Real-life Efficacy of Insulia® Tool in Patients Living With Type 2 Diabetes Treated With Basal Insulin Therapy as Part of a National Telemedicine Program (ETAPES)
Sponsored by Centre Hospitalier Sud Francilien
About this trial
Last updated 2 years ago
Study ID
2022/0004
Status
Completed
Type
Observational
Placebo
No
Accepting
18+ Years
All
Trial Timing
Ended 3 years ago
What is this trial about?
The purpose of this study was to evaluate the INSULIA digital tool (automation of basal
insulin dose calculation in type 2 diabetes) within the framework of a French national
telemedicine experimentation program (ETAPES) in a single-center study.
The assumption is that a better metabolic control with this tool.
What are the participation requirements?
Inclusion Criteria
- Age ≥ 18 years old.
- Patients with type 2 diabetes.
- Initiation or adjustment of basal insulin.
- Prescription of Insulia® for more than 6 months (between august 2018 and june 2021)
- Informed patient not opposed to the research